Neuralstem (CUR) Misses Q4 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. CVS
10. SPY

Go back to Neuralstem (CUR) Misses Q4 EPS by 1c

Neuralstem Reports Fiscal First Quarter 2016 Results and Business Update

May 9, 2016 8:05 AM EDT

GERMANTOWN, Md., May 9, 2016 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, reported its financial results for the three months ended March 31, 2016 and provided a business update.

Business Highlights

On May 6, 2016, the Company closed a public offering resulting in net proceeds of $7.42 million.  The net proceeds will be used for general corporate purposes, including the Phase 2 NSI-189 major depressive disorder (MDD) clinical trial and ongoing research and development... More